Skip to content

Precigen PGEN Accounts Payable

Accounts Payable at other companies

PVL
Palvella TherapeuticsPVLA
Roivant Sciences logo
Roivant SciencesROIV
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's accounts payable?
Precigen (PGEN) reported accounts payable of -$9.51M in Q1 2026.
How has Precigen's accounts payable changed year-over-year?
Precigen's accounts payable decreased by 8030.8% year-over-year, from -$117K to -$9.51M.
What is the long-term trend for Precigen's accounts payable?
Over 2 years (2021 to 2025), Precigen's accounts payable has grown at a 356.9% compound annual growth rate (CAGR), from $420K to $8.77M.